Detalhe da pesquisa
1.
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
Ann Oncol
; 22(12): 2591-2596, 2011 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-21421542
2.
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Clin Transl Oncol
; 17(2): 160-6, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25119930
3.
Raltitrexed in the treatment of elderly patients with advanced colorectal cancer: an active and low toxicity regimen.
Eur J Cancer
; 38(9): 1204-11, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12044507
4.
Phase II study of carboplatin and 1-h intravenous etoposide and paclitaxel in a novel sequence as first-line treatment of patients with small-cell lung cancer.
Lung Cancer
; 39(1): 77-84, 2003 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-12499098
5.
Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer.
Cancer Chemother Pharmacol
; 54(6): 546-52, 2004 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-15316749
6.
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
Cancer Chemother Pharmacol
; 64(2): 379-84, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19139896
7.
A prospective observational study of the effectiveness, safety, and effect on fatigue of darbepoetin alfa for the treatment of chemotherapy-induced anaemia.
Curr Med Res Opin
; 24(10): 2931-42, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18775103
8.
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Ann Oncol
; 17(8): 1205-12, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16766587
9.
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Br J Cancer
; 93(11): 1230-5, 2005 Nov 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-16265344